The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable.
Alkermes (NASDAQ:ALKS) has drugs of its own but is probably most famous for its drug delivery platforms to create extended-release drugs. The biotech gets royalties from Johnson & Johnson's schizophrenia drugs, Risperdal Consta and Invega, among others.
GW Pharmaceuticals (NASDAQ:GWPH) is developing drugs for epilepsy and other nervous system issues using chemicals derived from marijuana. Unlike the typical medical marijuana stocks that are cashing in on the legalization of its use, GW Pharmaceuticals is really a biotech because it's running clinical trials and seeking FDA approval for its drugs.
Valeant Pharmaceuticals (NYSE:VRX) is a specialty pharma, most famous at the moment for trying to buy Allergan. The drug company has grown substantially over the years through acquisitions and even became a foreign company though its acquisition of Canada-based Biovail.
Watch the following video to see whether senior biotech specialist Brian Orelli and health-care analyst David Williamson give the companies a goal, raise a yellow card, or send them off with a red card.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Brian Orelli has no position in any of the stocks mentioned. David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Nike and recommends BMW, Johnson & Johnson, and Nike. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.